In this paper, we review the history of Dengue, the mechanism of infection, the molecular characteristics and components of Dengue, the mechanism of entry to the target cells, cyclization of the genome and replication process, as well as translation of the proteins for virus assembly. The major emphasis of this work is on natural products and plant extracts, which were used for as palliative or adjuvant treatment of Dengue. This review article also summarizes the latest findings in regards to the marine products as effective drugs to target different symptoms of Dengue. Furthermore, an update on synthetic drugs for treating Dengue is provided in this review. As a novel alternative, we describe monoclonal antibody therapy for Dengue management and treatment.
INTRODUCTION

Dengue Infection, An Overview
Dengue fever is a serious infectious illness that is threatening several countries around the world. There are around 390 million cases of Dengue infection reported every year [1] . Before 1970, only nine countries had experienced severe Dengue epidemics. Nowadays, more than 100 countries are at risk of this fatal illness, which is equivalent to 40% of the entire world population. Several factors including climate change, unreliable water supplies, high connectivity of the world through daily flights, and poor sanitary conditions are responsible for the outbreak of Dengue all across the globe. Dengue fever (DF) is an infectious disease characterized by muscle and bone pain, nausea, rash, fatigue, and high fever as the initial symptoms of the illness. Dengue can develop into two acute phases namely: Dengue Shock Syndrome (DSS) and Dengue Hemorrhagic Fever (DHF).
In the acute phases of the illness, patients may suffer from internal bleeding, fluid leakage from the vessels, low platelet count, increased levels of cytokines, and shock [2] . The occurrence of DSS and DHF is also highly documented in 1780 in Philadelphia, in 1897 in Australia, in 1910 in Beirut, in 1916 in Taiwan and in 1928 in Greece 3. Dengue fever is caused by infection with any of the five serotypes of Dengue Virus (DENV).
HISTORY OF DENGUE
One of the first medical records that describe the symptoms of this disease was identified in a Chinese Medical Encyclopedia (an ancient book that was comprised of 30 volumes) by the Jin Dynasty, in 992 B.C. Originally, this disease was found in Southeast Asia, but the shipping commerce during 18th and 19th centuries promoted an increase in the outbreak of the disease. The first documented Dengue epidemics occurred concurrently in Africa, Asia, and North America in 1780. However, it was not until 1789 that the first identification of the disease happened. The first established case identifying Dengue dates back to 1789 by Dr. Benjamin Rush (a renowned American physician). Dr. Rush was the first scientist who coined the term "break-bone fever" for Dengue [4] for its symptoms of myalgia and arthralgia [3] , while the term Dengue was not still used. The roots of the word, Dengue, are not fully defined. Nonetheless, there are several hypotheses for its origins. Some believe it is from the Swahili expression Ka-dinga pepo, which means cramp-like seizure caused by an evil spirit and it was used in Zanzibar (the East African coast) to describe an illness throughout its outbreak between 1823 and 1870 [3] . Another theory speculates that the name denga was used by the slaves for this illness when they arrived at the New World. In 1827, it was called the "Dandy Fever", and in 1828, it was renamed as dunga in Cuba which later on renamed as Dengue. The Spanish recognized that Dengue was the same illness recorded previously, in 1801 in Spain.
During World War II, urbanization drastically contributed to the outbreak of this illness [5] . Although Dengue has been reported for centuries, it was not until 1943 that DENV for the first time was isolated by inoculation of patient's serum in mice by two Japanese physicians, Dr. Ren Kimura and Dr. Susumu Hotta [6] . In 1945, the polish/American virologist, Albert Bruce Sabin and his group isolated three different virus strains from Hawaii, India, and New Guinea and showed that these strains were antigenically similar and this virus serotype was called DENV-1 [7] . The virus isolated by Kimura was also identified as DENV-1. DENV-2 serotype was first reported in 1944 in Papua New Guinea and Indonesia, followed by the Philippines in 1954 and 1956, whereas DENV-3 and DENV-4 were first reported in 1953 in the Philippines and Thailand. Until 2013, a total number of 1,956 DENV-1 cases of isolation and identification were mapped by Messina et al. worldwide [8] . In October 2013, a novel dengue virus serotype was detected during the screening of viral samples taken from a 37-year-old farmer admitted in hospital in Malaysia. According to the genetic sequence of the virus and by phylogenetic analysis, the virus was different from the four original serotypes [9] .
MECHANISM OF INFECTION
Various evidence suggest a long association between DENV and human beings throughout past centuries [10] . Its transmission includes a sylvatic, enzootic cycle between nonhuman primates and arboreal mosquitoes [11] . The genus Aedes is the main vector for this virus and its two species, Aedes albopictus and Aedes aegypti are the main vectors for transmission of the disease to human. Dengue mosquitos use stored water for reproduction. Subsequently, poor management of wastewater and/or stored water resources could be major contributors to the Dengue outbreak. Current worldwide geographic connection and co-circulation of Dengue serotypes create an out-of-control situation in managing Dengue spread [9] . From the 1960s to the present, the geographic spread of Dengue in different countries has been substantially growing in addition to the number of serotypes identified in each region as well as the movement of vectors. Anthropological factors such as urbanization, global traveling patterns, and commercialization are other contributing factors to the widespread of Dengue [5] . Dengue could become a global life-threatening issue if Dengue mosquitos become resistant to the cold environments thus spreading in novel geographic zones.
MOLECULAR CHARACTERISTICS OF THE VIRUS
General Characteristics of the Virus
Genetic analysis suggests that all four serotypes of DENV evolved individually from ancestral sylvatic viruses hence became ecologically and evolutionarily distinct [11] . DENV is a class IV virus with a positive sense (+) single RNA strand, it is a member of the Flavivirus genus of the Flaviviridae family (other members of this family include the West Nile virus, Yellow Fever, Zika and the Japanese encephalitis) [12] . DENV contains 10 genes, 3 for structure and 7 for non-structural proteins. The viral genome is enclosed into a nucleocapsid. DENV has an icosahedral viral envelope with the approximate diameter of 50 nm formed by two main glycoproteins, E (envelope) and M (membrane) (Fig. 1A) [13] . The structure was defined by cryoelectron microscopy and electron density mapping. The capsid protein (C) is the first gene encoded by the genome, followed by M and E. The seven non-structural proteins are: NS1, NS2A, N2B, NS3, NS4A, NS4B and NS5. The size of the genome is around 11 kilobases flanked by untranslated regions (UTR) at 5' and 3' with a cap structure at the 5' end [14] [15] . During infection of DENV, the structure presents some alterations that modify the virus morphology (Fig. 1B) , particularly at 37°C, suggesting that these changes may help to activate infectious processes [16] . It is believed that the ancestor of the viruses from Flaviviridae family has emerged about 1000 years ago in an infectious cycle involving non-human primates. Around a few hundred years ago, however, transmissions to human have occurred via unknown factors.
MOLECULAR COMPONENTS OF THE DENV
Un-translated Regions
Numerous studies have recognized that RNA elements within the UTRs are key for virus replication, translation and pathogenesis in host and vector cells. DENV 5′UTRs are around 95 to 101 nucleotides long ( Fig. 2A) that contain two RNA domains with separate roles during viral RNA synthesis. In the 5' terminus (Fig. 2B) , there is a structure called a large stem-loop or SLA, this region acts as a promoter for the NS5 protein (RdRp). Another domain in this region is the short stem-loop (SLB), which contains sequences involved in replication and RNA-RNA interaction. Other elements include the 5′ and 3′ upstream AUG region (UAR), a 3′ cyclization sequence, 3′ short hairpin structure (SHP), the highly-conserved 3′SL and the 5′ cyclization sequence, and the capsid-coding region hairpin element (cHP) [17] .
At the 3' end (Fig. 2C) there are three domains of approximately 450 bases long that contain a highly variable region with different extension among serotypes (from 50-120 nucleotides) and is called Domain I [18] . The second domain (II) has a dumbbell structure (DB) and conserved sequences named CS2 and repeated CS2 (RCS2) common in the borne-mosquito Flaviviridae family [19] . The role of this domain is related to the RNA synthesis and viral translation. Finally, Domain III is the most conserved sequence, which contains the CS1 element, involved in the RNA-RNA interaction [20] . Finally, the 3′ terminal structure contains a short stem-loop of 14 nucleotides (SHP) followed by a large stem-loop of 79 bases pairs. A highly conserved feature of DENV is the presence of complementary sequences (CS). The 5′ CS element was found within the viral Open Reading Frame (ORF) whereas the complementary 3′CS was identified within the 3′UTR. Both regions and adjacent nucleotides are necessary for DENV genome cyclization [21] [22] . [13] . This structure denotes the conformation of external virus geometry. Dengue virus has around 250 A radius and it has between 3 and 4 subunits of E glycoprotein, which forms the main external shell of the virus. (B) Open structure of Dengue virus 16. When DENV is incubated at 37 °C, it changes the surface from smooth to rough and the E shell protein is more expanded as shown by the arrows.
Capsid Protein
The DENV capsid is a protein of 12 kDa that forms homo-dimers in solution. Structural studies showed that the monomer has four α-helices whereas the dimer shows asymmetric charge distribution. Helices α2 and α4 of one monomer are antiparallel to helices α2 and α4 of the other monomer. The capsid is the first protein encoded in the viral genome. Furthermore, it contributes to RNA rearrangements and binds the nucleic acid with high affinity (Kd=20 nm). The capsid is crucial for nucleo-capsid (NC) formation, which is the core of virus and contains one single copy of the genome [23] .
Membrane Protein
The membrane protein consists of 75 amino acids with M W approximately 9 kDa, making it the second smallest proteins in DENV. The membrane (M) and envelope (E) proteins from the external surface of the mature virus particle. The membrane protein is derived from the precursor M protein (prM) via cleavage of the original protein. The prM protein of retention prevents the membrane insertion, suggesting that this protein is originally present on the virus surface [24] .
Envelope Protein
The E protein is responsible for participation in cell recognition and the E protein is responsible for participation in cell recognition and cell entry through the membrane. This protein is arranged in a herringbone pattern as a series of 90 homo-dimers on the virion surface [25] . Several reports have revealed multiple functions of E protein in host receptor attachment, cellular uptake of the virion, and membrane fusion. In the endoplasmic reticulum (ER), E protein of DENV undergoes N-linked glycosylation at two asparagines, N67 and N153 located in Domain II and Domain I, respectively [26] . The N67 glycosylation site is unique to DENV and has been proposed to interact directly with DC-SIGN, one of the host cell receptors in dendritic [27] . A ribbon diagram of the crystal dimer of protein E is shown below (Fig. 3) with domains. The structures in black are the high-mannose-type carbohydrates, which may interact with more than one sugar from cellular receptors for efficient internalization of the virus. Fig. (3) . Envelope protein structure [28] . This image denotes a ribbon diagram of the crystal dimer of the E protein structure with the Domains I, II, and III, which are colored in red, green, and blue, respectively. The structures in black are the high-mannose-type carbohydrates. The structure was obtained by X-ray diffraction method with a resolution of 2.61 Å and computational analysis.
Nonstructural Protein (NS1)
The non-structural protein-1 (NS1) is an indispensable gene that produces a highly conserved 48 kDa glycoprotein among several members of the Flaviviridae family (Fig. 4) [29] which is secreted at high concentrations during viral replication 30. This protein is found both intracellularly and in a soluble form (sNS1) secreted from infected host cells. The immature form of NS1 is that of a monomer that is variably glycosylated [26] . It is considered that the main oligomeric form of sNS1 is a hexamer of ca. 300 kDa. This hexamer has 3 dimeric subunits non-covalently bound and is less stable than the soluble form of NS1 dimers, which are secreted [31] . The soluble form of NS1 can be detected in the peripheral blood from 9 to 18 days from the onset of the disease. Therefore, detection of this protein by typical immunoassay or immunochromatography methods are, currently, the main diagnostics approach for Dengue [32] . NS1 dimer with one subunit is shown in blue and other subunits are colored by domain (green, red and orange) (Fig. 4) . Fig. (4) . Non-structural protein 1 (NS1) structure [33] . This structure was resolved by X-RAY diffraction with a resolution of 3 Å. The NS1 dimer is constructed around an extended central β-sheet domain (in orange). A small "β-roll" dimerization domain (orange) is a mini structure of two β-hairpins. The second domain of each monomer projects from the central β-domain like a "wing" (green and blue). The β-roll and β-connector subdomain (red) of the wing form a protrusion on one face of the β-ladder with the spaghetti loop (aqua).
Nonstructural Protein 2A (NS2A)
The non-structural protein-2 (NS2A) is an essential component of the viral replication complex and for viral RNA synthesis. It also functions in virion assembly and antagonizes the host immune response [34] . NS2A is a small (molecular mass, 22 kDa) hydrophobic transmembrane protein (Fig. 5) , it has eight predicted transmembrane segments (pTMS1 to -8) and five integral transmembrane segments (pTMS3, -4, and -6 to -8) that span the lipid bilayer of the endoplasmic reticulum (ER) membrane [35] . NS2A interacts with NS1, and this complex is able to inhibit viral RNA synthesis by two possible mechanisms: (i) By altering the conformation of NS2A and thus prevent its interactions with other viral and host factors, leading to a loss of viral RNA synthesis or (ii) The uncleaved NS1-NS2A might attenuate the function of NS1, which is essential for viral RNA synthesis [36] . Fig. (5) . Non-structural protein 2A (NS2A) structure [34] . Structure of the NS2A protein determined by nuclear magnetic resonance (NMR). NS2A is a component of the viral replication complex that functions in active virus assembly. Two main alpha-helices are denoted in yellow and greenblue.
Nonstructural Protein NS2B
The nonstructural protein 2B (NS2B) is a membrane protein located on the cell membrane. It mainly functions as the co-factor of NS3 protease to induce its activity [37] . Roughly, 40 amino acids from the cytosolic domain of NS2B are necessary for the catalytic activity of NS3. The complex of NS2B-NS3 plays a crucial role in viral maturation.
Nonstructural Protein NS3
DENV nonstructural protein 3 (NS3) is comprised of a serine protease domain and an RNA helicase domain, which has nucleotide triphosphatase activities that are essential for RNA replication and viral assembly [38] . As previously mentioned, NS3 requires NS2B as a cofactor for its enzymatic activity. The protease domain of NS3 consists of an N-terminal domain with a chymotrypsin-like fold with two β-barrels, each composed of six β-strands, with the catalytic triad (His51-Asp75-Ser135) located at the cleft between the two β-barrels [39] . NS3 is able to interact with NS5 protein [40] through a region that includes 50 amino acids at the C-terminal. The presence of these two proteins is dominant among all four DENV serotypes. The function of the NS3 C-terminal domain is an ATPase/helicase activity for unwinding the doublestranded RNA (dsRNA) intermediate and RNA 5′-triphosphatase activity for viral RNA 5′-capping reaction [41] .
Nonstructural Proteins 4A and 4B (NS4A and NS4B)
The nonstructural protein 4A (NS4A) is a protein with 127 amino acids and it has two transmembrane domains (TMDs): the first 48 amino acids of NS4A form an amphipathic helix that mediates oligomerization [42] . NS4B consists of 248 amino acids and contains three TMDs [43] . NS4A and NS4B perform multiple tasks in viral replication and virus-host interactions [44] . NS4B protein physically interacts with NS3 and NS4A [45] . Membrane proteins NS4A and NS4B are linked by a conserved 23-amino-acid-long signal peptide whereas NS2B and NS3 are required for the proteolytic processing of DENV nonstructural proteins [ 46] .
Nonstructural Protein 5 (NS5)
The DENV NS5 is the largest (102 kDa) and the most conserved protein across flaviviruses with ~70% identical sequence among the four serotypes [47] . This protein is expressed during infection by DENV. The NS5 protein has three major functional domains: the Nterminal S-adenosyl methionine methyltransferase (MTase), the nuclear localization sequences (NLS), and the RNA-dependent RNA polymerase activity in its Cterminal domain. The MTase spans amino acid residues 1 to 239 and is responsible for guanine N-7 and ribose 2'-O-methylations required for the capping of the DENV genome. The cap structure is recognized by the host cell translational machinery (Fig. 6 ).
MOLECULAR MECHANISMS OF EN-TRANCE, INFECTION AND MULTIPLICATION OF VIRUS
After infection, DENV invades different cell types such as dendritic cells, monocytes, B-cells, T-cells, endothelial cells and macrophages. The receptors for DENV protein include HSP90, HSP70, mannose recep-tor, CD14 associated protein, DC-SIGN among other candidates. In this review, we briefly describe the three steps of DENV invasion into the cells.
Fig. (6).
Non-structural protein 5 (NS5) structure or methyltransferase [48] . Structure of the NS5 obtained by X-ray diffraction method with a resolution of 2.4 Å. This protein has the AdoMet-binding motif I located at residues 77-86. The region of the C-terminal polymerase domain containing motifs I to VIII of positive-strand RNA virus RNA polymerases. The methyltransferase domain of the NS5 is responsible for two sequential methylations of the 5'-RNA cap (denoted as small chain inside the enzyme, the small molecules are methyl groups).
DENGUE VIRUS ENTRY TO TARGET CELLS
The initial steps in Dengue virus entry are divided into adsorption and penetration. First, DENV promotes an interaction virus-cell receptor binding by the viral E glycosylated protein. The two asparagine (N)-linked glycosylation sites at positions Asn-67 and Asn-153, are unique for DENVs and highly conserved in most flaviviruses. This glycosylation pattern differs according to DENV serotype and affects the antigenic properties of the virus. A combination of factors such as pH, temperature, compositions of the medium and/or ionic strength plays an important role during the attachment of the virus to the cell. Therefore, the virus enters the host cell by receptor-mediated endocytosis. The initiation of infection requires the entrance of DENV virus into cells, followed by the release of nucleo-capsid. This process is completed by the fusion of viral membrane with a cellular membrane. Subsequently, the virus enters by clathrin-mediated endocytosis through endosomes. Through an acidification process and conformational changes in the E protein, the virus particle is released. Once inside, the enveloped virus unfolds releases the genome and the input positive-strand of vRNA is translated to a single polyprotein composed of the individual structural and NS proteins. Other studies suggest that soluble DENV NS1 attaches to cells primarily via an interaction with the glycosaminoglycans (GAG) heparan sulfate (HS) and chondroitin sulfate E (CS-E) and that GAG sulfation is necessary for binding. Particularly, purified DENV enveloped protein domains reportedly interact with HS suggesting that heparan sulfate proteoglycans (HSPGs) are dengue virus receptors on endothelial cells [49] [50] .
CYCLIZATION OF THE GENOME AND REP-LICATION
Genome uncoating involves dissociation of the capsid, which frees the RNA that is directly used for viral translation. RNA synthesis is catalyzed by the viral polymerase NS5 in a process that requires specific promoter recognition and genome cyclization [51] [52] . The presence of 5′ and 3′ complementary sequences in the genome of flaviviruses is a requirement for viral replication. These sequences have been suggested to allow the ends of the genome to associate through base pairing, leading to circular conformations of the RNA. The conformation of the viral RNA, in which the complementary sequences are hybridized, is known as panhandle-like structure [22] . The SLA structure present at the viral 5′UTR was found to be essential for specific NS5 polymerase binding and activity [14] . Moreover, the interaction of specific nucleotides of the SLA promoter with NS5 induces a conformational change in the protein, yielding a catalytically active enzyme. Thus, linear and circular conformations of the viral RNA co-exist and that dynamic RNAs are required for viral replication.
TRANSLATION OF PROTEINS
Viral protein synthesis takes place in the rough endoplasmic reticulum (RER). Basically, NS5 RdRp performs de novo RNA synthesis (production of a new RNA molecule) to first generate negative polarity RNA from the positive-stranded viral RNA template. Many series of translation produce high levels of proteins that together with vRNA are assembled into virions. The viral polyprotein is cleaved co-translationally and posttranslationally into at least 10 mature proteins. DENV induces intracellular membrane modifications in the cytoplasm forming vesicle packets (VPs) or smooth membrane structures (SMS), where the viral replication complex (RC) accumulates [53] . After the formation of these structures, the viral RC anchors and the Cterminal regions of C, prM, and E contain hydrophobic amino acids serves as signal sequences for insertion of the remaining protein. The NS2B-NS3 protease cleaves the structural proteins and NS1 protein into individual membrane-bound proteins. The NS3 protein with its cofactor NS2B acts as serine-protease needed for polyprotein-processing. This heterodimer protein complex cleaves on the cytoplasmic side of the ER membrane. The C-terminal end of the NS3 protein has three enzymatic properties: a 5' RNA-triphosphatase (RTP), a nucleoside triphosphatase (NTPase), and a helicase. NS3, as previously mentioned, forms a complex with NS5 and assists in viral replication. The NS1 glycosylated dimer is transported to the Golgi apparatus where it is processed by carbohydrate trimming. Prior to secretion of new viral particles, the third structural protein prM is processed into the mature M protein in the trans-Golgi Network by furin protease. It is believed that prM protects the E proteins from pH-induced reorganization and premature fusion during secretion hence the maturation event is necessary for infectivity.
UPDATES IN DENGUE FEVER THERAPEU-TICS
Natural Products and Plant Extracts for Treatment of Dengue
Several drugs have been discovered from natural sources as plants, microorganisms, and marine organisms. Natural products isolated from plants have been an excellent source of secondary metabolites used in traditional medicine to prevent and treat several diseases [54] . More than 80 % of the population in Asian and African countries depends on traditional medicine for primary health care due to the economic and geographical constraints [55] .
Traditional medicine is the knowledge and experience, based on the theories, beliefs, and practices of indigenous cultures used to prevent, diagnose and to treat physical and mental diseases [56] . Traditional medicine based on plants and marine products have been used to treat Dengue and other viral infections. In Brazil, Philippines, Malaysia and Latin America, Dengue is treated by using natural medicine [57] [58] [59] . However, many plants and natural products have not been fully investigated. To date, few plants extracts and their phytochemicals have successfully been tested against viral diseases. Table 1 summarizes some of these natural products, along with their species, origins, families, and their anti-Dengue activity.
Several natural compounds described in traditional medicine have been studied for the development of new drugs to treat different diseases including viral infections including DF. Those natural products are obtained from plants, marine organisms and microorganisms. In this paper, we review the main compounds obtained from plants and marine sources, which offer activities against Dengue. Serotype 2 is the most studied of the four Dengue serotypes, as DENV-2 is known to be responsible for acute phases of Dengue such as DHF and DSS. Nonetheless, there are interesting studies on in vitro antiviral activity of plant extracts against DENV-1 or other serotypes [57, 104, 106] .
Flavonoids Compounds against Dengue
Previous studies confirmed that flavonoids derived from plants possess antiviral activity against DENV [81, 94, 10 ] 2. However, only a few papers are focused on the mechanism of action of such plant-extracted compounds. The family of flavonoids acts as inhibitors against DENV protease. As shown in Table 1 , flavonoids such as orientin, vicenin and luteolin identified on the methanolic extracts of Ocimum sanctum showed antiviral activity. Obtained apigenin 7-Omethylwogonin, onysilin and 3,4 dicaffeoylquinic acid from Andrographis paniculata have proven to have high antiviral activity against DENV.
Other flavonoids (luteolin, kampherol and quercetin) isolated from Mamordica charantia were investigated for their antiviral inhibitory activity on DENV-1 [ 57] . Flavonoids obtained from Pelargonium citrosum, Citrus limon (hesperidin, diosmin and eriocitrin; citrunobin, citflavanone and lonchocarpol-A), and from Cymbopogon citratus DC. Stapf (citral, luteolin, myrcene, quercetin, kaempferol and apigenine) in in vitro test have shown considerable antiviral inhibitory activity against DENV [57, [79] [80] . Furthermore, flavonoids such as fisetin and baicalein isolated from the root of Scutellaria baicalensis were tested in vitro and exhibited anti-DENV activities by inhibition of RNA polymerase [107] . Other flavonoids (panduratin A, 4-hydroxypanduratin A) found in Boesenbergia rotunda (L.) have showed inhibition of DENV-2 NS3 protease [68] . In vitro tests showed that panduratin had an inhibitory activity at a concentration of 80 ppm, while 4-Hydroxypanduratin A showed better inhibition at lower concentrations than 40 ppm [68] . Pinocembrin and chartaceones (a dialkylated flavanones) were isolated from Cryptocarya chartacea [78] . Polymerase activity of these compounds was assayed in vitro by monitoring the incorporation of radiolabeled guanosine into a homopolymeric cytosine RNA template. These flavanones exhibited significant DENV NS5 RdRp inhibiting activity, with IC50 ranging from 1.8 to 4.2 µM [78] .
Derrisin, mundulinol, isopomiferin, silymarin, flavobion, isosilybin and silydianin, flavonoids were isolated from Silybum marianum using in silico approaches and computational techniques. Previous studies have shown multi-target viral activities against hepatitis C virus, human papilloma virus (HPV), antibacterial activity against H. pylori, and cytotoxic activity on human cell lines panel, as well inhibitory activity against DENV. The most reactive phytochemical (isolated from S. marianum) against DENV4-NS4B was found to be silydianin [64] . Sanchez et al., 2000, isolated glabranine from Tephrosia spp., which has proven to have an inhibitory effect on DENV replication [102] . Flagellaria indica that belongs to family of flagellariaceae is a plant from Southeast Asia and Australia. Its flavonoids, alkaloids and terpenoids possess inhibitory activity against DENV-2 [75] . Flavonoids are able to inhibit viruses by inhibiting different routes. Flavonoids isolated from Vernonia cinerea possess high inhibitory activity against DENV-2 [71]. In the same study, apigenin, quercetin and kaempferol were isolated from Tridax procumbers, which have shown in vitro viral inhibition against DENV [71] .
Alkaloids against Dengue
Alkaloids are a group of phytochemicals obtained from plants with various activities including potential inhibitory activity against Dengue. Although the mechanism of action of alkaloids is not clearly known, they were found to reduce viral replication in the cells. Pentacyclic oxindole isolated from Unicaria tormentosa, a plant used in traditional medicine in Amazonia and Peru, reduces the activity of the viral DENV antigen [105] . On the other hand, Ukani et al, 1996 isolated the alkaloids atisine and atidine from the plant Aconitum heterophyllum, which were used in traditional medicine to treat a wide range of diseases including bronchitis, cough [60] . These compounds are known to have anti-helmintic activity against guinea worms while holding great promise against DENV as well. The alkaloids narlumicine, oxysanguinarine isolated from Fumaria indica have shown inhibitory activity against DENV4-NS4B and potential antibacterial activity against Helicobacter pylori [64, 73] . The alcoholic extracts obtained from the aerial part of Cissampelos pareira Linn and from the root of Coptis teeta have shown inhibitory activity against DENV-1, -2, -3, and -4 in in vitro and in vivo conditions [73] . Alkaloids, terpenoids, and flavonoids isolated from Flacuortia indica have shown antibacterial activity against Helicobacter pylori and have potential larvicidal activity against Dengue vector [65] . Rothan et al., (2014) studied the auricularine, anthraquinones, iridoid glycosides, tritepenoids, saponins, and alizarin isolated from Hedyotis auricularia, and they confirmed their inhibitory activity against DENV-2 [71] . Alkaloids such as skimmianine, γ-fagarin and haplopin, obtained from Myrtopsis corymbosa have shown inhibitory activity against DENV polymerase and DENV-NS5 91.
Essential Oils, Terpenoids, and Other Compounds for the Treatment of Dengue
Terpenes are organic compounds that are constituents of the essential oils that have proven to have various activities including antimicrobial, antiinflammatory, antioxidant, cytotoxic activity. To date, a number of anti-DENV terpenes have been reported for various activities including antimicrobial, antifungal, and cytotoxic activity [73, 77, 101, 104] . Terpenoids from Premna mucronata were reported to exhibit anti-DENV activity. However, this plant has been used in traditional medicine to treat malaria, cough, tuberculosis, and stomach disorders as well [ 73] . Furthermore, triterpenoids (azadirachtin, Nimbin, desacetylnimbin, desacetylsalannin, salannin) from Azadirachta indica that have shown antibacterial, antifungal and antimalarial activity also proved to have inhibitory activity against DENV NS2 and NS3 protease [66] [67] . The same effect, inhibiting DENV NS2B-NS3 protease, was shown by the sennosides A, B, C and D isolated from Cassia angustifolia [71] . Additionally, a number of terpenes (drosericarpone, teucladiol, 3-hydroxy-3-methyl glutaric acid, daucosterol), essential oils (carotol, δ-cadinene, β-eudesmol), and flavonoids (luteolin, pinocembrin) obtained from Cleome droserifolia were used to treat hyperglycemia, breast cancer cell line (MCF7), and colon cancer cell line (HCT116), which have been reported to act against multiple strains responsible for malaria, yellow fever, Dengue fever, DHF, and filariasis [77] .
Terpenoids from Anacolosa pervilleana (anacolosine, lupenopne, β-amyrone, S. sambunigrin) have shown inhibition of Chikungunya virus (CHIKV) and DENV replication by inhibition of NS5 polymerase [65] , while the quinone methide triterpene (Celastrol) from Tripterygium wilfordii suppressed DENV serotypes 1-4 replication by upregulating of IFN-α expression [104] . Moreover, sesquiterpenes from Cladogynos orientalis have shown inhibitory activity against DENV-2 [75], while triterpenes and sesquiterpenes obtained from Melissa officinalis and Tanacetum parthenium demonstrated inhibitory activity against DENV4-NS4B [64, 101] . Geraniin, an ellagitannin that is present in strawberries, raspberries, blueberries and almonds, was found in the extract of Nephelium lappaceum. The extract has been used in Japanese traditional medicine as an anti-diarrheic but also showed antiviral activity against DENV-2 [92] . From the aqueous extract of the leaves of Carica papaya, chymopapain and papain were isolated, which were used to treat digestive disorders. It was found that the extract C. papaya offers great potential for treating Dengue fever as well. Increased vascular permeability and abnormal bleeding are common symptoms of DHF phase that induces thrombocytopenia and bleeding with a consequent decrease in platelet count. A considerable number of patients experiencing DHF have their life at risk during this thrombocytopenic period. Therefore, it is important to increase the platelet count. An in vivo study conducted on the use of C. papaya leaf juice have shown Platelet-Activating Factor Receptor (PTAFR) and Arachidonate 12-lipoxygenase (ALOX 12) expression and a significant increase in the platelet count of the patients treated with this natural compound [70] . The same effect of increasing platelets and avoiding bleeding was found by studying Psidium guava leaves [55] .
Terpenes and essential oils from Tanacetum parthenium, Eupatorium spp., Trixis divaricate, and Tessaria absinthioides, which belong to the family of Asteraceae have shown antiviral effects against DENV [58, 81, 101] . Besides these activities, T. parthenium was used to treat fevers, migraine headaches, rheumatoid arthritis, stomach aches, as well as toothaches [101] . The extract of Hemigraphis reptans that belongs to the family of Acanthaceae has shown inhibitory activity against DENV [71] . Earlier observations confirmed that essential oils from plants (e.g. Cleome spp., Lantana spp., and Lippia spp.) possess antiviral activity against yellow fever, and Dengue [76, 81, [88] [89] . These essential oils include spathulenol, bicyclogermacrene, β-caryophyllene, α-humulene, humulene epoxide II and phytol, germecrene-D, spathulenol, geranial, and limonene.
From Alternanthera philoxeroides Griseb and Aloysia gratissima coumarin, cadinol, limonene oxide, and β-caryophyllene were isolated, which have antiviral activity against DENV [58, 61] . From Borneol, camphor, limonene, and β-pinene were isolated from heterotheca latifolia, which have antiviral activity against Junin virus (JUNV) and against DENV-2 [58] . Gallic acid, corilagen, geraniin, rutin, quercetin glucoside, quercetin rhamnoside, digalloylglucopyronside, trigalloylglucopyronside, and apigenin, were isolated from Phyllanthus spp., that were used for their antibacterial and anti-diabetic properties while offering great potentials for treatment of Dengue's four serotypes as well as hepatitis B and C [73, 92, 97] .
Marine Products for the Treatment of Dengue
Marine products, derived from organisms and aquatic plants, are excellent sources of medicinal antiviral agents for the development of therapeutic drugs to treat infectious diseases in humans [108] . A brief summary of the sources, the compounds of different marine products, and their anti-DENV activity are presented in Table 2 . Sulfated polysaccharides derived from marine algae and other marine organisms have attracted considerable interest in recent years due to their wide biological activities. Seaweed is an important source of bioactive compounds that can be used to treat Dengue.
Fucoidan, a sulfated polysaccharide isolated from Cladosiphon okamuranus, a brown seaweed found naturally in Okinawa, Japan, acarrageenans and agarans from Gymnogongrus griffithsiae (red seaweeds), and Gymnogongrus torulosus (algae) from Europe, Asia, South America and Australia have shown activities for inhibiting DENV-2 [81, [109] [110] [111] . Peridinin and Palythone A isolated from the zoanthid Palythoa mutuki have shown anti-Dengue virus activities [112] . Kappa carragenan from Meristiella gelidium showed inhibitory activity against DENV-2 [113] . Moreover, galactomannans obtained from Leucaena leucocephala have shown activities against yellow fever virus (YFV) and DENV-1, while diterpenes (dolastanes and ecodolastanes) isolated from Canistrocarpus cervicornis showed inhibitory activity against DENV-1 and DENV-3 [114] . Galactans, fucans, and xylomannans obtained from Cryptonemia crenulata, Grateloupia indica, Cystoseira indica and Gracilaria corticata showed inhibitory activity against DENV-2 [ [109] [110] [111] . The study of Pujol et al. (2002) confirmed the inhibitory activity against DENV-2 of polysaccharides containing monosaccharides including galactose, mannose, rhamnose, fucans, and xylomannans extracted from marine organisms [110] . A previous study by Ono et al., (2003) confirmed that the sulfated galactomannans extracted from Leucaena leucocephala and Mimosa scabrella possess inhibitory activity against DENV-1 and YFV. Alkaloids (kuroshines A and B) and compounds such as ecdysone, viticosterone E, ajugasterone C, 20-hydroxyecdysone, α-ecdysone, 24-dehydromakisterone A, 20-hydroxyecdysone 3-acetate, ponasterone A, 2-deoxyecdysterone, isolated from Zoanthus Kuroshio have shown antibacterial, anti-inflammatory, anti-osteoporotic, and human platelet aggregation inhibition, which place them among the great candidates for treating DF [115] .
Synthetic Drugs in Dengue Disease Therapeutics
One of the major challenges in the development of effective Dengue treatment or safe vaccines is the impaired adaptive response of antibody-dependent enhancement (ADE) of infection. Several studies were performed for the determination of DENV epitopes to understand Ab production and neutralization during the disease [118] [119] . Subsequently, management of clinical manifestations represents the actual approach for Dengue disease treatment. The WHO recommends three important actions to be taken for helping Dengue infected patients: fluid therapy, reducing bleeding complications, and targeting host immune response to prevent the complications of vascular leakage and hypovolemic shock [120] .
In case of fluid therapy, the colloids can provide volume by an increase of plasma oncotic pressure that allows the retention of fluid in the intravascular compartment. Some studies compared colloids application versus crystalloids finding no significant differences between the two approaches in children with DSS [121] . The bleeding due to thrombocytopenia (platelet < 150x109/L) during DHF is usually reduced between days 3-8 from the onset of illness. Management of severe thrombocytopenia is through avoiding trauma, strict bed rest, intramuscular injections, and use of nonsteroidal anti-inflammatory agents. The blood transfusion must be given with care due to the fluid overload risk [120] .
Several promising new therapies are in different phases of ongoing clinical trials. These candidates follow three main strategies: targeting the virus, improving the body's immune response, or weakening factors that are required for DENV replication. To translate the research advances into clinical practice, a more accurate diagnosis in different phases of Dengue and careful prognosis are essential [122] .
Therapies that target the immune response can be divided based on their activities. The trial of corticosteroids has shown inhibitory effects on phagocytes, T and B-lymphocytes, and a placebo-controlled trial has demonstrated no effects on cytokine levels, circulating viral proteins or platelet count during early infection [123] [124] . Also, intravenous Immunoglobulin is not recommended due to a low efficacy [125] [126] . To date, there are no anti-Dengue synthetic drugs available in the market. Table 3 summarizes some of the attempts in experimental stage.
Monoclonal Therapy
More recently monoclonal Ab (MoAb) therapy is being explored via in silico assays performed with humanized antibodies, which might become a novel alternative therapy for Dengue [122, 136] . The first approach was through the introduction of MGAWN1, the MoAb against flavivirus made for West Nile Virus targeting E protein. This humanized MoAb was administrated by single intravenous infusion in healthy volunteers in a phase I study proving to be a safe approach with neutralizing activities [137] . Some of these anti-E antibodies are group reactive (GR) among all flavivirus, while some others are complex reactive (CR), and type-specific (TS). They have specific sequences of E protein, which are recognizable by the Abs. The group of GR MoAbs is weakly neutralizing or nonneutralizing compared to the TS MoAbs. However, studying several Dengue epitopes suggests that this GR MoAbs with low avidity throughout primary response to DENV show high avidity thus potently neutralizing against the 4 serotypes [138] .
Latest developments introduce MoAbs that target E proteins, specific domain III, as well as humanized Abs, such as HuScFv. These MoAbs have shown an inhibitory effect on DENV-2 in respect to cellular infection, blocking the assembly, and virus entry tovero cells [139] . Application of human MoAb 2D22 is another experimental treatment for DENV-2. The results in a mouse model of antibody-enhanced severe Dengue disease demonstrated a binding of MoAb 2D22 to E proteins in the dimeric structure neutralizing the virus. Hence, it is suggested that the presented epitope could be a potential target for therapeutics of Dengue [119] . An alternative strategy to generate MoAbs was performed by Robinson et al. , where a nonimmunodominant epitope of E protein and domain III were employed to design Ab513 via the structureguided method. This antibody was shown to eliminate the thrombocytopenia in the humanized mouse model and to reduce viremia, and vascular leakage [ 140] . One of the main concerns in MoAb therapy is the possibility to induce ADE in secondary infections or crossreactivity. In vivo assays with humanized MoAbs derived from patients could induce such complications [141] .
CONCLUSION
After centuries of suffering from Dengue and its severe consequences, there is no cure for this fatal illness even to date. Variety of natural and synthetic products have been developed and tested to overcome partial symptoms of Dengue. Different compounds from the families of flavonoids, alkaloids, and essential oils, terpenoids were extracted from the plants to develop natural drugs for targeting Dengue. Different drug candidates from the family of marine products were also reported for their interesting activities against Dengue. Moreover, several classes of synthetic drugs were developed by different countries across the world. Monoclonal antibody therapy was introduced as a potential alternative for treatment of Dengue. Despite all the attempts, Dengue remains as an untreatable viral infection that requires further research from scientific communities across the globe. This review article pro-vides perceptions on the attempts addressing this global issue, valuable attempts that can open insights to the future of this international challenge. 
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